– FRANCE, Dijon – Oncodesign Precision Medicine (EPA: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, nominates Dr. Christophe Thurieau (Ph.D.) for his election to its Board as an Independent Director at the AGM on June 25, 2025.
About Dr. Christophe Thurieau
Dr. Christophe Thurieau holds a doctorate in biochemistry from the Pierre and Marie Curie University (Paris VI) and completed pre and postdoctoral training at Harvard Medical School in Boston, USA. He is Executive Director of Research at Servier, where he manages the research centers in France, Denmark, Hungary, and the USA.
Before joining Servier in April 2017, Dr. Christophe Thurieau worked at Ipsen from 1996 to 2017. After holding various positions of increasing responsibility in Research and Development at Ipsen, in 2009, he became President of Ipsen Innovation and SVP of Global Scientific Affairs. He is the author of more than 30 original research articles published in international scientific journals and holds 25 patents.
Dr. Christophe Thurieau said: “I am very proud to put my expertise at the service of OPM’s development as a member of the Board of Directors. OPM commitment to research and development, combined with the expertise of its teams, paves the way for major advances in the treatment of oncology patients and therapeutic resistance.”
About Oncodesign Precision Medicine (OPM)
Oncodesign Precision Medicine (OPM), founded in 2022, is a biopharmaceutical company specializing in precision medicine and dedicated to the discovery of treatments for resistant and metastatic cancers.
OPM currently has two kinase inhibitors in clinical trials: OPM-101, for the treatment of chronic immuno-inflammatory digestive diseases and immuno-oncology, demonstrated high target engagement and absence of toxicity in its phase I trial in healthy volunteers. Phase Ib/IIa is scheduled to start at the beginning of 2025. OPM-201, initially licensed out to Servier for the treatment of Parkinson’s disease, completed its Phase I trial in healthy volunteers in 2024 and returned to the OPM portfolio.
These two molecules come from the Nanocyclix® technology platform, which enables the design and selection of small macrocyclic kinase inhibitors that are highly effective and selective. Today, we have 12,000 molecules in our library and will be using AI to accelerate the discovery of drug candidates while reducing the cost of this phase.
OPM, co-founded by Philippe Genne, Jan Hoflack, and Karine Lignel, is based in Dijon, in the heart of the university and hospital cluster, and has 14 employees.
For more information: oncodesign.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.